Drug development is a complex, time-consuming and resource intensive process that often fails to cross the finish line.
Computer assisted drug design (CADD) has long failed to live up to it's promise to streamline that process and deliver truly insightful information to help design better drugs. HTuO's physics-based technology addresses the root of the issue.
Learn MoreFrom obesity to cancer, seemingly insurmountable medical challenges can be addressed through innovative solutions. However, focusing on seemingly undruggable targets introduces new technical difficulties. At HTuO Biosciences, we have developed a computational solution designed to empower research teams to overcome these challenges across the biopharmaceutical sector. Our mission is to transform challenges into breakthroughs.
About Us
Introducing high accuracy into modeling gives us and our partners the ability to address the challenges of drug design head-on. A more detailed understanding of how molecules interact allows for data-driven predictions of the best possible drug design - ultimately leading to fewer drugs failing and more efficacious drugs.
Learn more about our potential in the drug discovery & our long term vision.
Applications
We are happy to discuss any form of a collaboration to let you access our platform.
Partnerships
We are always on the lookout for talent. We’re open to fixed location and remote work. See Careers
Check our Careers page for open positions, and see if we have the right opportunity for you.
Open PositionsOctober 19, 2024
CEO Anthony Fejes is attending the JLABS Global CEO Summit in New York City. The three-day forum, held exclusively for JLABS company leaders, connects Johnson & Johnson executives, JPALs, dealmakers, entrepreneurs, and investors. The overarching goal of this exclusive event is to help companies bring their sciences and technologies to patients who need them most.
October 9, 2024
Our Director of Business Development, Mr. Jacek Mis, will be in Stockholm, Sweden, Nov 3-6 at the 2024 BIO-Europe. Connect with Jacek through the partnering portal or email us directly to learn about HTuO and our drug discovery goals.
August 21, 2024
HTuO Biosciences announces appointment of Mr. Neil Klompas to its Board of Directors. Neil is currently the President and CEO of Augurex Life Sciences, and has over 20 years of experience in the pharmaceutical industry. Read the press release here.